Surmodics (NASDAQ:SRDX) Posts Earnings Results, Beats Estimates By $0.04 EPS

Surmodics (NASDAQ:SRDX) posted its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04, Zacks reports. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%.

Surmodics Trading Up 0.6 %

Shares of SRDX opened at $34.06 on Friday. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26. The stock has a fifty day moving average price of $38.25 and a two-hundred day moving average price of $38.93. Surmodics has a 52-week low of $25.17 and a 52-week high of $42.44.

Wall Street Analysts Forecast Growth

Several brokerages have commented on SRDX. Needham & Company LLC reaffirmed a “hold” rating on shares of Surmodics in a research report on Thursday, January 30th. StockNews.com assumed coverage on shares of Surmodics in a research note on Monday. They set a “hold” rating for the company. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat, Surmodics has a consensus rating of “Hold” and an average price target of $50.00.

Insider Transactions at Surmodics

In related news, CFO Timothy J. Arens sold 7,009 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now owns 70,350 shares in the company, valued at $2,774,604. This represents a 9.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.90% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).